# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA approves Moderna's mRESVIA (mRNA-1345), an mRNA vaccine for RSV, for adults 60+. The second approved mRNA product from ...
https://www.ft.com/content/fad59eb1-2f34-47eb-b938-49ed12f12c45
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc ...
Wall Street opens with red showing as investors worry about interest rates. Volatility and Treasury yields spike. Traders expec...
Moderna Inc. (NASDAQ: MRNA) shares are trading lower Tuesday. The stock may be pulling back after gaining on bird flu concerns ...